Seeking Alpha

Shares of GenMark Diagnostics (GNMK -25%) get slammed after one of its customers, Natural...

Shares of GenMark Diagnostics (GNMK -25%) get slammed after one of its customers, Natural Molecular Testing, launches their laboratory developed comprehensive Personalized Medicine Panel using Luminex's (LMNX +6%) xMAP technology. Terms of the multi-year collaboration and license agreement were not disclosed.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|